Insulin Aspart [Protamine Crystallised]

Adults: Insulin Aspart starts working faster and acts for a shorter time than soluble human insulin. Because of this, it should generally be given immediately before a meal. When necessary, it may be given soon after a meal. The dosage is individual, and the physician decides it according to the patient's needs. Insulin Aspart should normally be used together with a long-acting insulin given at least once a day. The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related treatment, 50 to 70% of this requirement may be provided by Insulin Aspart and the rest by the long-acting insulin. The dosage may also need adjusting if the patient does more physical activity or changes the usual diet. Exercise straight after a meal may increase the risk of hypoglycaemia. Subcutaneous injection: it should be injected into the abdominal region, buttocks, thigh or upper arm. Its onset is more rapid and its activity shorter than human regular insulin, so inject it immediately (within 5 to 10 minutes) before a meal. Continuous Subcutaneous Insulin Infusion (CSII) by external pump: Insulin Aspart can also be infused subcutaneously by an external insulin pump. The initial programming of the pump should be based on the total daily insulin dose of the previous regimen. Approximately 50% of the total dose is usually given as meal-related boluses of Insulin Aspart, and the remainder is given as a basal infusion. When it is used with an infusion pump, it should not be mixed with any other insulin. Intravenous use: Insulin Aspart can be given intravenously under medical supervision for glycemic control. Blood glucose and potassium levels must be monitored closely to avoid hypoglycemia and hypokalemia. For intravenous use, the concentration should be from 0.05 IU/mL to 1.0 IU/mL insulin aspart in infusion systems using polypropylene infusion bags. It has been shown to be stable in infusion fluids such as 0.9% sodium chloride.